We found that Shp1 loss in macrophages enhanced their ability to perform phagocytosis in vitro, which could be one mechanism that contributed to the observed increase in anti-tumor immunity following induced deletion of Ptpn6. Whether Ptpn6-deficient macrophages exhibit increased phagocytosis in the tumor microenvironment, and therefore could increase the activity of anti-tumor antibody therapies remains an exciting open research question. Here, PTPN6 is linked to neoplasm.